News for Biogen Inc. (BIIB)

These 50 STEM standouts on this list are actively advancing the world’s understanding of medicine, meteorology and large language models.

Summary On July 25, 2025, Biogen Inc (BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has

EMA's CHMP backs key drugs from KalVista, Biogen & Ionis for conditions like hereditary angioedema & postpartum depression. Read more here.

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. ( BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Me

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tariffs are wielded by Trump to leverage critical concessions and protect US interests. The pharma industry is one in which this leverage has had considerable success.

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on t

Summary Biogen Inc (BIIB) has announced its participation in the 2025 Alzheimer's Association International Conference (AAIC) from July 27-31 in Toronto, Canada

Biogen Inc.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.72%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures...

Biogen (BIIB) plans to enhance its manufacturing capabilities with a substantial $2 billion investment in North Carolina's Research Triangle Park (RTP). This ne

Investment builds on Biogen's 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025

Truist has revised its outlook on Biogen (BIIB), lowering its rating from "Buy" to "Hold" and cutting its price target to $142 from the previous $199. This chan

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the company’s pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline.

Kelly Dilts will leave Dollar General in August.

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings de

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bi

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programs CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.

[url="]Satellos Bioscience Inc.[/url] (TSX: MSCL, OTCQB: MSCLF) (”œSatellos” or the ”œCompany”), a biotech company developing new small molecule therapeu